Drug intelligence / Profile preview

OTX-002

Development stage: Preclinical
Lead developer: OncoBone Ventures
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

OTX-002 is an antibody-drug conjugate (ADC) being developed by OncoBone Therapeutics for the treatment of multiple myeloma (MM). Currently in the preclinical stage, it is part of the company's internal proprietary pipeline focusing on bone-related malignancies. While the specific molecular target and cytotoxic payload have not been publicly disclosed, the asset is undergoing proof-of-concept studies with an estimated timeline for out-licensing for clinical development in 2028.

Beyond the preview

Go deeper on OTX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTX-002.

Explore the full profile